Saltar a la navegació principal
Saltar a la cerca
Vés al contingut principal
Portal de Recerca de la Universitat Autònoma de Barcelona Inici
Ajuda i PMF
Català
Español
English
Inici
Perfils
Unitats de recerca
Projectes
Producció científica
Conjunts de dades
Tesis i Treballs supervisats
Cerca per experiència, nom o afiliació
CHARACTERIZATION OF THE SECONDARY DAMAGE AND EVALUATION OF NEW ANTIINFLAMMATORY TREATMENTS IN AN ANIMAL MODEL OF INTRACEREBRAL HEMORRHAGE BY MRI
Manich Raventos, Gemma
(PI)
Rojas Codina, Santiago
(Co-Investigador/a Principal)
Barrachina Esteve, Oriol
(Col.laborador/a)
Segura Torres, Annabel
(Col.laborador/a)
Calvet Soler, Claudia
(Col.laborador/a)
Departament de Ciències Morfològiques
Informació general
Fingerprint
Fingerprint
Explora els temes de recerca tractats en aquest projecte. Les etiquetes es generen en funció dels ajuts rebuts. Juntes formen un fingerprint únic.
Ordenar per
Ponderació
Alfabèticament
Keyphrases
Anti-inflammatory Therapy
100%
Intracerebral Hemorrhage
100%
Secondary Damage
100%
Magnetic Resonance Imaging
100%
Peripheral Markers
25%
Imaging Sequences
16%
Anti-inflammatory Drugs
16%
Leukotriene Receptor Antagonist
16%
Oxidative Stress
16%
Inflammation
16%
Clinical Trials
16%
Lipoxygenase Inhibitors
8%
Tocilizumab
8%
Tissue Damage
8%
Clinical Management
8%
Tofacitinib
8%
T2-FLAIR
8%
Conventional Magnetic Resonance Imaging
8%
Iron Toxicity
8%
Iron Accumulation
8%
TNF Inhibitors
8%
C5 Protein
8%
Putative Drug Targets
8%
IL-6 Inhibitor
8%
Ruxolitinib
8%
Etanercept
8%
Secukinumab
8%
Temporal Course
8%
Image Adjustment
8%
Zileuton
8%
Imaging Alterations
8%
Phosphodiesterase 4 Inhibitor
8%
Immunomodulatory Drugs (IMiDs)
8%
IL-17 Inhibitors
8%
Anakinra
8%
Inflammation Markers
8%
Damage Process
8%
Damage Markers
8%
Phosphodiesterase-4 (PDE4)
8%
Proton Spectroscopy
8%
Hematoma
8%
Imaging Marker
8%
Roflumilast
8%
T1-T2
8%
Advanced Magnetic Resonance Imaging
8%
Blood-brain Barrier
8%
Janus Kinase 1 (JAK1)
8%
Montelukast
8%
Glial Activation
8%
Inflammatory Molecules
8%
Magnetization Transfer
8%
Cause of Disability
8%
Eculizumab
8%
Target Marker
8%
JAK Inhibitors
8%
Toxicity Stress
8%
New Drugs
8%
High Cost
8%
Temporal Evolution
8%
Therapeutic Target
8%
Tumor Necrosis Factor-α
8%
Interleukin-17 (IL-17)
8%
Kurtosis
8%
Proteinase Inhibitor
8%
1H-MRS
8%
Causes of Mortality
8%
AIMS™
8%
Interleukin-23 (IL-23)
8%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Hemorrhage
100%
Inflammation
25%
Phosphodiesterase IV Inhibitor
16%
Leukotriene Receptor Blocking Agent
16%
Clinical Trial
16%
Interleukin 17
8%
Lipoxygenase Inhibitor
8%
Roflumilast
8%
Hematoma
8%
Iron
8%
Bleeding
8%
Etanercept
8%
Anakinra
8%
Secukinumab
8%
Tissue Injury
8%
Eculizumab
8%
Ruxolitinib
8%
Antiinflammatory Agent
8%
Tofacitinib
8%
Tocilizumab
8%
Janus Kinase Inhibitor
8%
Zileuton
8%
Tumor Necrosis Factor Inhibitor
8%
Montelukast
8%
Anti-Inflammatory Drug
8%
Iron Poisoning
8%
Disease
8%
Protein Inhibitor
8%
Blood-Brain Barrier
8%